Eli Lilly and Co reports results for the quarter ended June 30 - Earnings Summary

• Eli Lilly and Co LLY.N reported quarterly adjusted earnings of $6.31​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $3.92. The mean expectation of eighteen analysts for the quarter was for earnings of $5.46 per share. Wall Street expected results to range from $5.27 to $5.70 per share.

• Revenue rose 37.6% to $15.56 billion from a year ago; analysts expected $14.71 billion.

• Eli Lilly and Co's reported EPS for the quarter was $6.29​.

• The company reported quarterly net income of $5.66 billion.

• Eli Lilly and Co shares had fallen by 4.3% this quarter and lost 3.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.9% in the last three months.​

• In the last 30 days, seven analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Eli Lilly and Co is $972.50, about 23.3% above its last closing price of $746.37

This summary was machine generated from LSEG data August 7 at 03:35 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)